CDC25C and breast carcinoma: To our knowledge, this is the first report describing the mechanism whereby the Chk1-activated p21-Cdc25C-Cdc2 signaling pathway plays a key role in regulating cell cycle progression in diosgenin-treated Hs578T breast cancer cells that are functionally deficient of p53 (Figure 5).